Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2018-06-14 Director's Dealing
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-06-14 English
FORM 4 SUBMISSION
Director's Dealing
2018-06-14 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 13, 2018, reporting the submission of matters to a vote of security holders at the company's annual meeting. It details the voting results for director elections and ratification of the independent auditor. The document is short (3646 characters) and focuses on official voting results from the annual meeting. It does not contain financial statements or detailed financial data, nor is it a full annual report or earnings release. The content matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-06-14 English
SCHEDULE 13D/A - AMENDMENT NO. 3 (EXIT FILING)
Major Shareholding Notification
2018-05-15 English
8-K FOR Q1 2018 EARNINGS RELEASE
Earnings Release Classification · 95% confidence The document is a Form 8-K filed by Novus Therapeutics, Inc. dated May 11, 2018. It announces the company's financial results for the quarter ended March 31, 2018, and includes a press release as Exhibit 99.1. The text explicitly states that the press release is furnished as an exhibit and incorporated by reference, indicating this document is an announcement of earnings results rather than the full earnings report itself. The document length is 3873 characters, which is relatively short and consistent with an earnings release announcement rather than a comprehensive financial report. Therefore, this document fits the definition of an Earnings Release (ER) as it is the initial announcement of quarterly financial results with key highlights only.
2018-05-11 English
10-Q
Interim / Quarterly Report Q1 2018
2018-05-11 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.